Table of Contents
Advances in Otolaryngology
Volume 2014 (2014), Article ID 185617, 8 pages
http://dx.doi.org/10.1155/2014/185617
Review Article

The Potential Use of Melatonin for Preventing Cisplatin Ototoxicity: An Insight for a Clinical Approach

University of Brasília, 70680-395 Brasília, DF, Brazil

Received 16 May 2014; Revised 15 July 2014; Accepted 24 July 2014; Published 18 August 2014

Academic Editor: Tino Just

Copyright © 2014 Juliana Gusmão de Araujo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. P. Rybak, D. Mukherjea, S. Jajoo, and V. Ramkumar, “Cisplatin ototoxicity and protection: clinical and experimental studies,” Tohoku Journal of Experimental Medicine, vol. 219, no. 3, pp. 177–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Ravi, S. M. Somani, and L. P. Rybak, “Mechanism of cisplatin ototoxicity: antioxidant system,” Pharmacology & Toxicology, vol. 76, no. 6, pp. 386–394, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Bokemeyer, C. C. Berger, J. T. Hartmann et al., “Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer,” British Journal of Cancer, vol. 77, no. 8, pp. 1355–1362, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. L. P. Rybak, “Mechanisms of cisplatin ototoxicity and progress in otoprotection,” Current Opinion in Otolaryngology and Head and Neck Surgery, vol. 15, no. 5, pp. 364–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. P. Rybak, K. Husain, C. Morris, C. Whitworth, and S. Somani, “Effect of protective agents against cisplatin ototoxicity,” The American Journal of Otology, vol. 21, no. 4, pp. 513–520, 2000. View at Google Scholar · View at Scopus
  6. L. Riedemann, C. Lanvers, D. Deuster et al., “Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin,” Pharmacogenomics Journal, vol. 8, no. 1, pp. 23–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H.-J. Kim, G.-S. Oh, J.-H. Lee et al., “Cisplatin ototoxicity involves cytokines and STAT6 signaling network,” Cell Research, vol. 21, no. 6, pp. 944–956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Ekborn, Cisplatin-induced ototoxicity. Pharmacokinetics, prediction and prevention, 2003.
  9. C. M. Franceschi de, T. Tochetto, A. F. Silveira Da, M. R. Fantinel, and T. D. Algarve, “Cisplatin effects on guinea pigs: cochlear histology and genotoxicity,” Brazilian Journal of Otorhinolaryngology, vol. 77, no. 6, pp. 728–735, 2011. View at Google Scholar
  10. R. J. Reiter, D. X. Tan, L. C. Manchester, M. Pilar Terron, L. J. Flores, and S. Koppisepi, “Medical implications of melatonin: receptor-mediated and receptor-independent actions,” Advances in Medical Sciences, vol. 52, pp. 11–28, 2007. View at Google Scholar · View at Scopus
  11. M. A. Lopez-Gonzalez, J. M. Guerrero, F. Rojas, and F. Delgado, “Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants,” Journal of Pineal Research, vol. 28, no. 2, pp. 73–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Reiter, D. Tan, R. M. Sainz, J. C. Mayo, and S. Lopez-Burillo, “Melatonin: reducing the toxicity and increasing the efficacy of drugs,” Journal of Pharmacy and Pharmacology, vol. 54, no. 10, pp. 1299–1321, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-H. Kim, S.-J. Jeong, B. Kim, S.-M. Yun, D. Y. Choi, and S.-H. Kim, “Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells,” Journal of Pineal Research, vol. 52, no. 2, pp. 244–252, 2014. View at Publisher · View at Google Scholar
  14. P. Lissoni, S. Barni, M. Mandalà et al., “Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status,” European Journal of Cancer, vol. 35, no. 12, pp. 1688–1692, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Gonzalez, A. del Castillo-Vaquero, A. Miro-Moran, J. A. Tapia, and G. M. Salido, “Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology,” Journal of Pineal Research, vol. 50, no. 3, pp. 250–260, 2011. View at Google Scholar
  16. A. Galano, D. X. Tan, and R. J. Reiter, “Melatonin as a natural ally against oxidative stress: a physicochemical examination,” Journal of Pineal Research, vol. 51, no. 1, pp. 1–16, 2011. View at Google Scholar
  17. J. Fukutomi, A. Fukuda, S. Fukuda, M. Hara, A. Terada, and M. Yoshida, “Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species,” Life Sciences, vol. 80, no. 3, pp. 254–257, 2006. View at Google Scholar
  18. D.-X. Tan, L. C. Manchester, M. P. Terron, L. J. Flores, and R. J. Reiter, “One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?” Journal of Pineal Research, vol. 42, no. 1, pp. 28–42, 2007. View at Publisher · View at Google Scholar
  19. L.-F. Ye, Z.-Z. Tao, Q.-Q. Hua et al., “Protective effect of melatonin against gentamicin ototoxicity,” The Journal of Laryngology & Otology, vol. 123, no. 6, pp. 598–602, 2009. View at Google Scholar
  20. C. Rodriguez, J. C. Mayo, R. M. Sainz et al., “Regulation of antioxidant enzymes: a significant role for melatonin,” Journal of Pineal Research, vol. 36, no. 1, pp. 1–9, 2004. View at Google Scholar
  21. J. Espino, J. A. Pariente, and A. B. Rodríguez, “Oxidative stress and immunosenescence: therapeutic effects of melatonin,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 670294, 9 pages, 2012. View at Publisher · View at Google Scholar
  22. M. Karasek, “Melatonin, human aging, and age-related diseases,” Experimental Gerontology, vol. 39, no. 11-12, pp. 1723–1729, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. R. J. Reiter, D. Tan, J. C. Mayo, R. M. Sainz, J. Leon, and Z. Czarnocki, “Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans,” Acta Biochimica Polonica, vol. 50, no. 4, pp. 1129–1146, 2003. View at Google Scholar · View at Scopus
  24. L. Lin, Q.-X. Huang, S.-S. Yang, J. Chu, J.-Z. Wang, and Q. Tian, “Melatonin in Alzheimer’s disease,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 14575–14593, 2013. View at Publisher · View at Google Scholar
  25. J. M. Olcese, C. Cao, T. Mori et al., “Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease,” Journal of Pineal Research, vol. 47, no. 1, pp. 82–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Z. Wang and Z. F. Wang, “Role of melatonin in Alzheimer-like neurodegeneration,” Acta Pharmacologica Sinica, vol. 27, no. 1, pp. 41–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Srinivasan, D. P. Cardinali, U. S. Srinivasan et al., “Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection,” Therapeutic Advances in Neurological Disorders, vol. 4, no. 5, pp. 297–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Lin, Y. Du, S. Yuan, J. Shen, X. Lin, and Z. Zheng, “Serum melatonin is an alternative index of Parkinson’s disease severity,” Brain Research, vol. 1547, pp. 43–48, 2014. View at Google Scholar
  29. G. Rocchitta, R. Migheli, G. Esposito et al., “Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease,” Journal of Pineal Research, vol. 40, no. 3, pp. 204–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Gitto, M. Karbownik, R. J. Reiter et al., “Effects of melatonin treatment in septic newborns,” Pediatric Research, vol. 50, no. 6, pp. 756–760, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. A. M. Sánchez-Sánchez, V. Martín, G. García-Santos et al., “Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells,” Free Radical Research, vol. 45, no. 11-12, pp. 1333–1341, 2011. View at Publisher · View at Google Scholar
  32. R. M. Sainz, J. C. Mayo, C. Rodriguez, D. X. Tan, S. Lopez-Burillo, and R. J. Reiter, “Melatonin and cell death: differential actions on apoptosis in normal and cancer cells,” Cellular and Molecular Life Sciences, vol. 60, no. 7, pp. 1407–1426, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Cos, A. González, C. Martínez-Campa, M. D. Mediavilla, C. Alonso-González, and E. J. Sánchez-Barceló, “Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions,” Cancer Detection and Prevention, vol. 30, no. 2, pp. 118–128, 2006. View at Publisher · View at Google Scholar
  34. A. N. Viswanathan and E. S. Schernhammer, “Circulating melatonin and the risk of breast and endometrial cancer in women,” Cancer Letters, vol. 281, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Hill, T. Frasch, and T. Duplessis, “Molecular mechanisms of melatonin anticancer effects,” Integrative Cancer Therapies, vol. 8, no. 4, pp. 337–346, 2009. View at Publisher · View at Google Scholar
  36. A. Korkmaz, E. J. Sanchez-Barcelo, D. X. Tan, and R. J. Reiter, “Role of melatonin in the epigenetic regulation of breast cancer,” Breast Cancer Research and Treatment, vol. 115, no. 1, pp. 13–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Song, A. J. Kim, H. Kim et al., “Melatonin suppresses doxorubicin-induced premature senescence of A549 lung cancer cells by ameliorating mitochondrial dysfunction,” Journal of Pineal Research, vol. 53, no. 4, pp. 335–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Lissoni, M. Chilelli, S. Villa, L. Cerizza, and G. Tancini, “Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial,” Journal of Pineal Research, vol. 35, no. 1, pp. 12–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Casado-Zapico, V. Martín, G. García-Santos et al., “Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients,” Journal of Pineal Research, vol. 50, no. 3, pp. 345–355, 2011. View at Google Scholar
  40. I. Bejarano, P. C. Redondo, J. Espino et al., “Melatonin induces mitochondrial-mediated apoptosis in human myeloid HL-60 cells,” Journal of Pineal Research, vol. 46, no. 4, pp. 392–400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Trubiani, R. Recchioni, F. Moroni, J. Pizzicannella, S. Caputi, and R. di Primio, “Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation,” Journal of Pineal Research, vol. 39, no. 4, pp. 425–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Rubio, F. Estévez, J. Cabrera, R. J. Reiter, J. Loro, and J. Quintana, “Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells,” Journal of Pineal Research, vol. 42, no. 2, pp. 131–138, 2007. View at Publisher · View at Google Scholar
  43. G. García-Santos, I. Antolín, F. Herrera, V. Martín, J. Rodriguez-Blanco, and M. del Pilar Carrera, “Melatonin induces apoptosis in human neuroblastoma cancer cells,” Journal of Pineal Research, vol. 41, no. 2, pp. 130–135, 2006. View at Google Scholar
  44. V. Martín, G. García-Santos, J. Rodriguez-Blanco et al., “Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death,” Cancer Letters, vol. 287, no. 2, pp. 216–223, 2010. View at Publisher · View at Google Scholar
  45. V. Martín, F. Herrera, P. Carrera-Gonzalez et al., “Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin,” Cancer Research, vol. 66, no. 2, pp. 1081–1088, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Wang, H. Hao, L. Yao et al., “Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells,” Journal of Pineal Research, vol. 53, no. 2, pp. 180–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Casado-Zapico, J. Rodriguez-Blanco, G. García-Santos et al., “Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway,” Journal of Pineal Research, vol. 48, no. 1, pp. 72–80, 2014. View at Google Scholar
  48. G. García-Santos, V. Martin, J. Rodríguez-Blanco et al., “Fas/Fas ligand regulation mediates cell death in human Ewings sarcoma cells treated with melatonin,” British Journal of Cancer, vol. 106, no. 7, pp. 1288–1296, 2012. View at Google Scholar
  49. B. H. Ali and M. S. Al Moundhri, “Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research,” Food and Chemical Toxicology, vol. 44, no. 8, pp. 1173–1183, 2006. View at Publisher · View at Google Scholar
  50. M. Hara, M. Yoshida, H. Nishijima et al., “Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats,” Journal of Pineal Research, vol. 30, no. 3, pp. 129–138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Sener, L. Kabasakal, S. Arbakb, S. Onerb, F. Ercanb, and M. K. Uysal, “The protective effect of melatonin on cisplatin nephrotoxicity,” Fundamental & Clinical Pharmacology, vol. 14, pp. 553–560, 2000. View at Google Scholar
  52. U. Kilic, E. Kilic, Z. Tuzcu et al., “Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway,” Nutrition & Metabolism, vol. 10, no. 1, article 7, 2013. View at Google Scholar
  53. H. Parlakpinar, E. Sahna, M. K. Ozer, F. Ozugurlu, N. Vardi, and A. Acet, “Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury,” Journal of Pineal Research, vol. 33, no. 3, pp. 161–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. K. E. Atalik, B. Keleş, Y. Uyar, M. A. Dündar, M. Oz, and H. H. Esen, “Vasoprotection by melatonin and quercetin in rats treated with cisplatin,” Indian Journal of Experimental Biology, vol. 48, no. 12, pp. 1188–1193, 2010. View at Google Scholar
  55. Y. O. Ilbey, E. Ozbek, A. Simsek, A. Otunctemur, M. Cekmen, and A. Somay, “Potential chemoprotective effect of melatonin in cyclophosphamide- and cisplatin-induced testicular damage in rats,” Fertility and Sterility, vol. 92, no. 3, pp. 1124–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Ateşşahin, E. Sahna, G. Türk et al., “Chemoprotective effect of melatonin against cisplatin-induced testicular toxicity in rats,” Journal of Pineal Research, vol. 41, no. 1, pp. 21–27, 2006. View at Publisher · View at Google Scholar
  57. M. A. Lopez-Gonzalez, J. M. Guerrero, R. Torronteras, C. Osuna, and F. Delgado, “Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs,” Journal of Pineal Research, vol. 28, no. 1, pp. 26–33, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. O. W. Guthrie, “Aminoglycoside induced ototoxicity,” Toxicology, vol. 249, no. 2-3, pp. 91–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. J.-B. Kim, J. Y. Jung, J.-C. Ahn, C. K. Rhee, and H. Hwang, “Antioxidant and anti-apoptotic effect of melatonin on the vestibular hair cells of rat utricles,” Clinical and Experimental Otorhinolaryngology, vol. 2, no. 1, pp. 6–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Bas, T. R. Van De Water, C. Gupta et al., “Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses,” British Journal of Pharmacology, vol. 166, no. 6, pp. 1888–1904, 1888. View at Publisher · View at Google Scholar
  61. T. Erdem, O. Ozturan, M. Iraz, M. C. Miman, and E. Olmez, “Dose-dependent dual effect of melatonin on ototoxicity induced by amikacin in adult rats,” European Archives of Oto-Rhino-Laryngology, vol. 262, no. 4, pp. 314–321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. J. G. Kalkanis, C. Whitworth, and L. P. Rybak, “Vitamin E reduces cisplatin ototoxicity,” Laryngoscope, vol. 114, no. 3, pp. 538–542, 2004. View at Google Scholar
  63. S. A. Tokgöz, E. Vuralkan, N. D. Sonbay et al., “Protective effects of vitamins E, B and C and L-carnitine in the prevention of cisplatin-induced ototoxicity in rats,” The Journal of Laryngology & Otology, vol. 126, no. 5, pp. 464–469, 2012. View at Google Scholar
  64. G. Simşek, S. A. Tokgoz, E. Vuralkan, M. Caliskan, O. Besalti, and I. Akin, “Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats,” European Archives of Oto-Rhino-Laryngology, vol. 270, no. 6, pp. 1789–1793, 2013. View at Publisher · View at Google Scholar
  65. T. Erdem, T. Bayindir, A. Filiz, M. Iraz, and E. Selimoglu, “The effect of resveratrol on the prevention of cisplatin ototoxicity,” European Archives of Oto-Rhino-Laryngology, vol. 269, no. 10, pp. 2185–2188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. A. L. L. Sampaio, M. A. Dias, A. R. Venosa, P. L. Tauil, E. Alencar, and C. A. C. P. Oliveira, “The Effect of Gingko Biloba (EGB 761) as an otoprotector against cisplatin ototoxicity,” Otolaryngology—Head and Neck Surgery, vol. 149, supplement 2, pp. P222–P223, 2013. View at Publisher · View at Google Scholar
  67. B. A. Abdel-Wahab and S. M. Abd El-Aziz, “Ginkgo biloba protects against intermittent hypoxia-induced memory deficits and hippocampal DNA damage in rats,” Phytomedicine, vol. 19, no. 5, pp. 444–450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Huang, C. A. Whitworth, and L. P. Rybak, “Ginkgo Biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats,” Otology & Neurotology, vol. 28, no. 6, pp. 828–833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. S. J. Choi, S. W. Kim, J. B. Lee et al., “Gingko biloba extracts protect auditory hair cells from cisplatin-induced ototoxicity by inhibiting perturbation of gap junctional intercellular communication,” Neuroscience, vol. 244, pp. 49–61, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. M. A. Hyppolito, M. Rossato, and F. Holanda, “Ototoxicidade da cisplatina e otoproteção pelo extrato de ginkgo biloba às células ciliadas externas: estudo anatômico e eletrofisiolόgico,” Brazilian Journal of Otorhinolaryngology, vol. 69, no. 4, pp. 504–511, 2003. View at Google Scholar
  71. C. J. Tian, Y. J. Kim, S. W. Kim, H. J. Lim, Y. S. Kim, and Y.-H. Choung, “A combination of cilostazol and Ginkgo biloba extract protects against cisplatin-induced Cochleo-vestibular dysfunction by inhibiting the mitochondrial apoptotic and ERK pathways,” Cell Death and Disease, vol. 4, no. 2, p. e509, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. S. J. Hong, G. J. Im, J. Chang et al., “Protective effects of edaravone against cisplatin-induced hair cell damage in zebrafish,” International Journal of Pediatric Otorhinolaryngology, vol. 77, no. 6, pp. 1025–1031, 2013. View at Publisher · View at Google Scholar
  73. O. Kuduban, C. Kucur, E. Sener, H. Suleyman, and F. Akcay, “The role of thiamine pyrophosphate in prevention of cisplatin ototoxicity in an animal model,” The Scientific World Journal, vol. 2013, Article ID 182694, 5 pages, 2013. View at Publisher · View at Google Scholar
  74. G. Lorito, S. Hatzopoulos, G. Laurell et al., “Dose-dependent protection on cisplatin-induced ototoxicity—an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model,” Medical Science Monitor, vol. 17, no. 8, pp. BR179–BR186, 2011. View at Publisher · View at Google Scholar
  75. K. C. M. Campbell, R. P. Meech, L. P. Rybak, and L. F. Hughes, “The effect of D-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection,” Journal of the American Academy of Audiology, vol. 14, no. 3, pp. 144–156, 2003. View at Google Scholar · View at Scopus
  76. K. D. Korver, L. P. Rybak, C. Whitworth, and K. M. Campbell, “Round window application of D-methionine provides complete cisplatin otoprotection,” Otolaryngology—Head and Neck Surgery, vol. 126, no. 6, pp. 683–689, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. M. G. Riga, L. Chelis, S. Kakolyris et al., “Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy,” The American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 36, no. 1, pp. 1–6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. H. J. Jeong, Y. Choi, M. H. Kim et al., “Rosmarinic acid, active component of dansam-eum attenuates ototoxicity of cochlear hair cells through blockage of caspase-1 activity,” PLoS ONE, vol. 6, no. 4, Article ID e18815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Celebi, M. M. Gurdal, M. H. Ozkul, H. Yasar, and H. H. Balikci, “The effect of intratympanic vitamin C administration on cisplatin-induced ototoxicity,” European Archives of Oto-Rhino-Laryngology, vol. 270, no. 4, pp. 1293–1297, 2013. View at Google Scholar
  80. M. Paksoy, E. Ayduran, A. Sanlı, M. Eken, S. Aydin, and Z. A. Oktay, “The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats,” Medical Oncology, vol. 28, no. 2, pp. 615–621, 2011. View at Google Scholar
  81. D. Murphy and S. J. Daniel, “Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model,” Otolaryngology: Head and Neck Surgery, vol. 145, no. 3, pp. 452–457, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. A. G. Shafik, R. H. Elkabarity, M. T. Thabet, N. B. Soliman, and N. K. Kalleny, “Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs,” Auris Nasus Larynx, vol. 40, no. 1, pp. 51–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. G. W. Hill, D. K. Morest, and K. Parham, “Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections,” Otology & Neurotology, vol. 29, no. 7, pp. 1005–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus